Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

31 Oct 2017

Abstract excerpt

Abstract Background: Breast cancer patients who do not respond to neoadjuvant therapy have a poor prognosis. There is a pressing need for novel targets and models for preclinical testing. Here we report characterization of breast cancer patient-derived xenografts (PDX) largely generated from residual tumors following neoadjuvant chemotherapy. Experimental Design: PDXs were derived from surgical samples of primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to CAR-T cell therapy research
Share to Cell Image Analysis Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29093017
DOI: 10.1158/1078-0432.ccr-17-0615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type TumorsPMID 29093017Read ↗

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancerSemantic proximity Read ↗

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.Semantic proximity Read ↗

A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitorsSemantic proximity Read ↗

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read ↗

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapySemantic proximity Read ↗

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.Semantic proximity Read ↗

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency SignatureSemantic proximity Read ↗

The Promise of Combining Inhibition of PI3K and PARP as Cancer TherapySemantic proximity Read ↗

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read ↗

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Semantic proximity Read ↗

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.Semantic proximity Read ↗

Machine learning-based prediction of response to PARP inhibition across cancer typesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.